Flexion Therapeutics Inc
FLXN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.21B
Close$
$11.64
51.7% downside
Current Fair Value
51.7% downsideOvervalued by 51.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.21 Billion |
|---|---|
| Enterprise Value | $1.32 Billion |
| Dividend Yield | $2.33 (10.45%) |
| Earnings per Share | $-2.66 |
| Beta | 0.08 |
| Outstanding Shares | 50,265,000 |
Return
| Return on Equity | 122.27% |
|---|---|
| Return on Assets | -46.22% |
| Return on Invested Capital | -45.12% |
Valuation & Multiples
| P/E Ratio | -9.05 |
|---|---|
| PEG | -39.31 |
| Price to Sales | 24.08 |
| Price to Book Ratio | -12.04 |
| Enterprise Value to Revenue | 13.14 |
| Enterprise Value to EBIT | -16.8 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | -3.04 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Flexion Therapeutics Inc
CEO: Michael Clayman